CRISPRa Stable Cell Lines


Our promise to you:
Guaranteed product quality, expert customer support.


CRISPRa Stable Cell Lines    

CRISPRa (CRISPR activation) system is a technology based on the improved CRISPR/Cas9 system that uses a synthetic programmable transcription factor to initiate endogenous transactivation of genes. In mammalian cells, the expressing of dCas9 (a nuclease-deficient Cas9 only retaining DNA binding activity) fused with a transcriptional activation domain, and gRNA complementary to the target promoter region in the genome, will result in increased transcription of the corresponding gene.

CRISPR/Cas9 PlatformCB, with many years of experience in gene editing, has recently introduced custom CRISPRa cell line service to help researchers achieve transcriptional activation of target genes by dCas9-VPR system in the shortest period of time.

  • dCas9-VPR system

In the dCas9-VPR protein, the activation domains of the p65 subunit of NFκB and Epstein−Barr virus R Transactivator (Rta) are added to the C-terminus of dCas9-Vp64, and the expression of the targeted gene is increased to a greater extent than the three transcription factors compared to dCas9-Vp64.

Strategy of CRISPRa is described as follows

TSS: transcriptional start siteTSS: transcriptional start site

Workflow of CRISPRa stable cell lines

➢ Design an activation strategy based on your needs
➢ Design and synthesize specific gRNA targeted to specific promotor region
➢ Transfection
➢ Screening monoclonal strain
➢ Identify monoclonal strains by PCR and sequencing, and screen the successfully edited cell lines
➢ Amplification, cryopreservation and delivery

Our scientists have extensive experience with >500 distinct cell lines and are very familiar with their culture conditions and genetic backgrounds. We provide variety of cell lines according to your requirements, including normal cell lines, cancer cells, primary cells, etc.

Successfully modified mammalian cell lines by CRISPR/Cas9 PlatformCB

  • Blood Lineage Cells (RAW264.7, HMC1.2, K562, U937 etc.)
  • Cancer Cell Lines (HEK293, HEK293T, Hela, MCF7, Neuro2a, HepG2, U87 etc.)
  • Stem Cells (iPSC)
  • Other Cell Lines (NIH3T3, MCF10, HEME, SW10 etc.)


  • Strong transcriptional activation in multiple cell lines
  • Functional genomics/target validation
  • Unbiased positive genetic screening
    Include cell-based survival/proliferation, sensitivity to drugs or toxins, screening of fluorescent reporter genes and single-cell transcriptomes
  • Drug discovery and screening goals
  • Immunotherapy research

Why choose CRISPR/Cas9 PlatformCB?

  • Novel CRISPR strategy for higher efficiency and success rate (>98%)
  • Professional multiple cell lines culture protocols
  • Rich experience — more than thousands of genetic editing project experience
  • Shorter turnaround time and lower price
  • Milestone update/report and final report
  • Custom deliverables — homozygous/hybrid clones

CRISPR/Cas9 PlatformCB has successfully obtained thousands of CRISPR/Cas9 cell lines from over 200 different cell models, including easy-to-transfect cells and hard- to-transfect cells. Tell us about your project needs and we will provide you with a fully custom CRISPRa stable cell line from strategic design to the ultimate stable cell line. We are committed to providing our customers with the most reliable and efficient research services to best meet your research goals, with reduced turnaround time and lower prices. If you have any question, please feel free to contact us.

For research use only. Not intended for any clinical use.